ASCO Genitourinary Cancers Symposium


 

ASCO GU 2022 on EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment With Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible MIBC

185 views
March 23, 2022
Comments 0
Login to view comments. Click here to Login